VIGAMOX® Solution treats bacterial conjunctivitis caused by susceptible strains.


Preservative-free formulation


Broad-spectrum activity that targets the following bacterial strains:

  • Staphylococcus aureus
  • Staphylococcus epidermidis
  • Streptococcus pneumoniae
  • Haemophilus influenzae
  • Chlamydia trachomatis

Rigorous clinical investigations

  • Proven efficacy in multiple clinical trials

VIGAMOX® Solution is widely available and ready for your patients.
Connect with us through email and talk to a Harrow representative in your area.

Contact Us



VIGAMOX® (moxifloxacin HCI ophthalmic solution) 0.5% as base is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species,* Micrococcus luteus,* Staphylococcus aureus, S. epidermidis, S. haemolyticus, S. hominis, S. warneri,* Streptococcus pneumoniae, S. viridans group, Acinetobacter lwoffii,* Haemophilus influenzae, H. parainfluenzae,* Chlamydia trachomatis (*efficacy for this organism was studied in fewer than 10 infections).

Dosage and Administration

Instill one drop in the affected eye 3 times a day for 7 days.

Warnings and Precautions

  • Hypersensitivity Reactions – In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. If an allergic reaction to moxifloxacin occurs, discontinue use of the drug.
  • Prolonged Use – Prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy.
  • Avoidance of Contact Lens Wear – Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.

Adverse Reactions

In VIGAMOX® Solution clinical trials, the most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1–6% of patients. Nonocular adverse events reported at a rate of 1–4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.

You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For more information, please view the Full Prescribing Information for Vigamox, please visit vigamox.com/prescribinginformation.

Reference: 1. Vigamox. Prescribing information. Harrow IP, LLC; 2023.


No questions left unanswered

If you have any questions about VIGAMOX®,
call us at 1-833-442-7769
. You can also fill out the
form below and click submit.

*Required Field.